| Cyclin-dependent kinase 1 |
IC50 |
= |
50.0 |
nM |
Inhibitory concentration against Cyclin dependent kinase 1. |
CHEMBL1136199 |
| MCF7 |
IC50 |
= |
10700.0 |
nM |
Cytotoxic property against MCF-7 cell line was determined |
CHEMBL1136199 |
| K562 |
IC50 |
= |
9000.0 |
nM |
Cytotoxic property against K562 cell line was determined |
CHEMBL1136199 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
35000.0 |
nM |
Binding affinity to cyclin-dependent kinase 1 (CDK1) |
CHEMBL1135432 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
35000.0 |
nM |
Binding affinity to cyclin-dependent kinase 1 (CDK1) |
CHEMBL1135432 |
| Cyclin-dependent kinase 1/cyclin B |
IC50 |
= |
4.0 |
nM |
Inhibition of Cyclin B-cyclin-dependent kinase 1 |
CHEMBL1135432 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
70.0 |
nM |
Inhibition of Cyclin A-cyclin-dependent kinase 2 |
CHEMBL1135432 |
| Cyclin-dependent kinase 2/cyclin E |
IC50 |
= |
35.0 |
nM |
Inhibition of Cyclin E-cyclin-dependent kinase 2 |
CHEMBL1135432 |
| Cyclin-dependent kinase 4/cyclin D1 |
IC50 |
= |
850.0 |
nM |
Inhibition of Cyclin D1-cyclin-dependent kinase 4 |
CHEMBL1135432 |
| MAP kinase ERK1 |
IC50 |
= |
9000.0 |
nM |
Inhibition of Mitogen-activated protein kinase 3 (MAPK-ERK1) |
CHEMBL1135432 |
| MAP kinase ERK2 |
Inhibition |
|
|
% |
Inhibition of Mitogen-activated protein kinase 1 (MAPK-ERK2) (no data) |
CHEMBL1135432 |
| cAMP-dependent protein kinase (PKA) |
IC50 |
= |
9000.0 |
nM |
Inhibition of cAMP-dependent protein kinase |
CHEMBL1135432 |
| Unchecked |
IC50 |
> |
10000.0 |
nM |
Inhibition of cGMP-dependent protein kinase |
CHEMBL1135432 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
4.0 |
nM |
Inhibition of Cyclin-dependent kinase 2 (CDK2) |
CHEMBL1136209 |
| Cyclin-dependent kinase 1/cyclin B |
IC50 |
= |
50.0 |
nM |
Inhibition of recombinant Cyclin-dependent kinase 1-cyclin B |
CHEMBL1134966 |
| MCF7 |
IC50 |
= |
10700.0 |
nM |
In vitro cytotoxic effect on MCF-7 cancer cell line |
CHEMBL1134966 |
| K562 |
IC50 |
= |
9000.0 |
nM |
In vitro cytotoxic effect on K562 cancer cell line |
CHEMBL1134966 |
| CCRF-CEM |
IC50 |
= |
7400.0 |
nM |
In vitro cytotoxic effect on CEM cancer cell line |
CHEMBL1134966 |
| HOS |
IC50 |
= |
22000.0 |
nM |
In vitro cytotoxic effect on HOS cancer cell line |
CHEMBL1134966 |
| G-361 |
IC50 |
= |
24000.0 |
nM |
In vitro cytotoxic effect on G361 cancer cell line |
CHEMBL1134966 |
| Cyclin-dependent kinase 1/cyclin B |
IC50 |
= |
4.0 |
nM |
In vitro inhibitory activity against Cyclin-dependent kinase 1-cyclin B complex from starfish oocytes |
CHEMBL1132992 |
| Protein kinase Pfmrk |
IC50 |
= |
26000.0 |
nM |
Inhibitory activity against Plasmodium falciparum cyclin dependent protein kinase, Pfmrk |
CHEMBL1145071 |
| Plasmodium falciparum |
IC50 |
= |
9200.0 |
nM |
Inhibitory activity against Plasmodium falciparum W2 |
CHEMBL1145071 |
| Plasmodium falciparum |
IC50 |
= |
2600.0 |
nM |
Inhibitory activity against Plasmodium falciparum D6 |
CHEMBL1145071 |
| Unchecked |
IC50 |
= |
4.0 |
nM |
Inhibition of p34cdc2/cyclin B |
CHEMBL1145498 |
| Unchecked |
IC50 |
= |
423.0 |
nM |
Inhibition Cdk2/cyclin A |
CHEMBL1145498 |
| Unchecked |
IC50 |
= |
35.0 |
nM |
Inhibition of p33cdk2/cyclin E |
CHEMBL1145498 |
| Unchecked |
IC50 |
= |
75.0 |
nM |
Inhibition of Cdk5/p35 |
CHEMBL1145498 |
| NON-PROTEIN TARGET |
GI50 |
= |
2000.0 |
nM |
Growth inhibition human NCI60 cells |
CHEMBL1153829 |
| KM12 |
GI50 |
= |
76.0 |
nM |
Growth inhibition human KM12 cells |
CHEMBL1153829 |
| NCI-H522 |
GI50 |
= |
347.0 |
nM |
Growth inhibition human NCI-H522 cells |
CHEMBL1153829 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
4.0 |
nM |
Inhibition of human cdc2/cyclin B assessed as [32P] incorporation in histone H1 from [gamma32P]ATP |
CHEMBL1153829 |
| Cdc2 |
IC50 |
= |
40.0 |
nM |
Inhibition of starfish cdc2/cyclin B assessed as [32P] incorporation in histone H1 from 150 M [gamma32P]ATP |
CHEMBL1153829 |
| Cdc2 |
IC50 |
= |
500.0 |
nM |
Inhibition of starfish cdc2/cyclin B assessed as [32P] incorporation in histone H1 from 1.5 mM [gamma32P]ATP |
CHEMBL1153829 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
70.0 |
nM |
Inhibition of human cdk2/cyclin A |
CHEMBL1153829 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
35.0 |
nM |
Inhibition of human cdk2/cyclin E |
CHEMBL1153829 |
| Cyclin-dependent kinase 4/cyclin D1 |
IC50 |
= |
850.0 |
nM |
Inhibition of human cdk4/cyclin D1 |
CHEMBL1153829 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
75.0 |
nM |
Inhibition of human cdk5/p35 |
CHEMBL1153829 |
| MAP kinase ERK1 |
IC50 |
= |
9000.0 |
nM |
Inhibition of human Erk1 |
CHEMBL1153829 |
| c-Jun N-terminal kinase, JNK |
IC50 |
> |
1000.0 |
nM |
Inhibition of human JNK |
CHEMBL1153829 |
| Protein kinase C alpha |
IC50 |
> |
10000.0 |
nM |
Inhibition of human PKCalpha |
CHEMBL1153829 |
| Protein kinase C beta |
IC50 |
> |
10000.0 |
nM |
Inhibition of human PKCbeta1 |
CHEMBL1153829 |
| Protein kinase C beta |
IC50 |
> |
10000.0 |
nM |
Inhibition of human PKCbeta2 |
CHEMBL1153829 |
| Protein kinase C gamma |
IC50 |
> |
10000.0 |
nM |
Inhibition of human PKCgamma |
CHEMBL1153829 |
| Protein kinase C delta |
IC50 |
> |
100000.0 |
nM |
Inhibition of human PKCdelta |
CHEMBL1153829 |
| Protein kinase C epsilon |
IC50 |
> |
100000.0 |
nM |
Inhibition of human PKCepsilon |
CHEMBL1153829 |
| Protein kinase C eta |
IC50 |
> |
100000.0 |
nM |
Inhibition of human PKCeta |
CHEMBL1153829 |
| Protein kinase C zeta |
IC50 |
> |
100000.0 |
nM |
Inhibition of human PKCzeta |
CHEMBL1153829 |
| Unchecked |
IC50 |
= |
9000.0 |
nM |
Inhibition of human cAMP-dependent protein kinase |
CHEMBL1153829 |
| Unchecked |
IC50 |
> |
10000.0 |
nM |
Inhibition of human cGMP-dependent protein kinase |
CHEMBL1153829 |
| Unchecked |
IC50 |
> |
3333.0 |
nM |
Inhibition of human casein kinase 1 |
CHEMBL1153829 |
| Glycogen synthase kinase-3 beta |
IC50 |
> |
10000.0 |
nM |
Inhibition of human GSK3-beta |
CHEMBL1153829 |
| Insulin receptor |
IC50 |
= |
5000.0 |
nM |
Inhibition of human insulin receptor |
CHEMBL1153829 |
| Casein kinase 2 |
IC50 |
> |
10000.0 |
nM |
Inhibition of human casein kinase 2 |
CHEMBL1153829 |
| Unchecked |
IC50 |
> |
1000.0 |
nM |
Inhibition of human Raf kinase |
CHEMBL1153829 |
| Unchecked |
IC50 |
> |
10000.0 |
nM |
Inhibition of human v-abl |
CHEMBL1153829 |
| Cell division control protein 28 |
IC50 |
= |
80.0 |
nM |
Inhibition of Saccharomyces cerevisiae cdc28 |
CHEMBL1153829 |
| Unchecked |
IC50 |
= |
4.0 |
nM |
Inhibition of starfish oocytes CDK1/cyclin B |
CHEMBL1143353 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
70.0 |
nM |
Inhibition of human recombinant CDK2/cyclin A expressed in baculovirus-infected insect cells |
CHEMBL1143353 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
75.0 |
nM |
Inhibition of human recombinant CDK5/p25 expressed in Escherichia coli |
CHEMBL1143353 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
|
|
|
Inhibition of human recombinant CDK7/cyclin H expressed in baculovirus-infected insect cells |
CHEMBL1143353 |
| CDK9/cyclin T1 |
IC50 |
|
|
|
Inhibition of human recombinant CDK9/cyclin T expressed in baculovirus-infected insect cells |
CHEMBL1143353 |
| Ribosomal protein S6 kinase alpha 1 |
Activity |
= |
74.0 |
% |
Percentage RSK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase p38 delta |
Activity |
= |
98.0 |
% |
Percentage p38delta activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase p38 gamma |
Activity |
= |
94.0 |
% |
Percentage p38-gamma activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PAK 4 |
Activity |
= |
43.0 |
% |
Percentage PAK4 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Rho-associated protein kinase 2 |
Activity |
= |
93.0 |
% |
Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PAK7 |
Activity |
= |
53.0 |
% |
Percentage PAK5 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PAK6 |
Activity |
= |
67.0 |
% |
Percentage PAK6 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| 3-phosphoinositide dependent protein kinase-1 |
Activity |
= |
79.0 |
% |
Percentage PDK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Unchecked |
Activity |
= |
85.0 |
% |
Percentage PHK activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PIM1 |
Activity |
= |
93.0 |
% |
Percentage PIM1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PIM2 |
Activity |
= |
96.0 |
% |
Percentage PIM2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PIM3 |
Activity |
= |
91.0 |
% |
Percentage PIM3 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| cAMP-dependent protein kinase alpha-catalytic subunit |
Activity |
= |
79.0 |
% |
Percentage PKA activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase AKT |
Activity |
= |
95.0 |
% |
Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase AKT2 |
Activity |
= |
92.0 |
% |
Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Protein kinase C alpha |
Activity |
= |
77.0 |
% |
Percentage PKCalpha activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Protein kinase C zeta |
Activity |
= |
83.0 |
% |
Percentage PKCzeta activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Protein kinase C mu |
Activity |
= |
85.0 |
% |
Percentage PKD1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Ribosomal protein S6 kinase alpha 3 |
Activity |
= |
71.0 |
% |
Percentage RSK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Ribosomal protein S6 kinase 1 |
Activity |
= |
87.0 |
% |
Percentage S6K1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Sgk1 |
Activity |
= |
82.0 |
% |
Percentage SGK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Myosin light chain kinase, smooth muscle |
Activity |
= |
86.0 |
% |
Percentage SmMLCK activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Tyrosine-protein kinase SRC |
Activity |
= |
14.0 |
% |
Percentage Src activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase SRPK1 |
Activity |
= |
79.0 |
% |
Percentage SRPK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
30.0 |
nM |
Inhibition of CDK2-cyclinA in the presence of 20uM ATP |
CHEMBL1150976 |
| Serine/threonine-protein kinase PAK 4 |
IC50 |
= |
130.0 |
nM |
Inhibition of PAK4 in the presence of 5uM ATP |
CHEMBL1150976 |
| Unchecked |
Activity |
= |
89.0 |
% |
Percentage AMPK activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Aurora-B |
Activity |
= |
89.0 |
% |
Percentage Aurora B activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Aurora-C |
Activity |
= |
85.0 |
% |
Percentage Aurora C activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| BR serine/threonine-protein kinase 2 |
Activity |
= |
76.0 |
% |
Percentage BRSK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| CaM kinase I alpha |
Activity |
= |
99.0 |
% |
Percentage CaMK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| CaM-kinase kinase alpha |
Activity |
= |
76.0 |
% |
Percentage CaMKKalpha activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| CaM-kinase kinase beta |
Activity |
= |
60.0 |
% |
Percentage CaMKKbeta activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Cyclin-dependent kinase 2/cyclin A |
Activity |
= |
9.0 |
% |
Percentage CDK2-cyclinA activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Chk1 |
Activity |
= |
95.0 |
% |
Percentage CHK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Chk2 |
Activity |
= |
94.0 |
% |
Percentage CHK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Casein kinase I delta |
Activity |
= |
103.0 |
% |
Percentage CK1delta activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Casein kinase II |
Activity |
= |
99.0 |
% |
Percentage CK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Tyrosine-protein kinase CSK |
Activity |
= |
82.0 |
% |
Percentage CSK activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Activity |
= |
88.0 |
% |
Percentage DYRK1A activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 2 |
Activity |
= |
91.0 |
% |
Percentage DYRK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 3 |
Activity |
= |
89.0 |
% |
Percentage DYRK3 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase EEF2K |
Activity |
= |
95.0 |
% |
Percentage EF2K activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase ERK1 |
Activity |
= |
95.0 |
% |
Percentage ERK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase ERK2 |
Activity |
= |
79.0 |
% |
Percentage ERK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Mitogen-activated protein kinase 15 |
Activity |
= |
70.0 |
% |
Percentage ERK8 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Glycogen synthase kinase-3 beta |
Activity |
= |
79.0 |
% |
Percentage GSK3-beta activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase NEK2 |
Activity |
= |
95.0 |
% |
Percentage NEK2a activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase NEK6 |
Activity |
= |
91.0 |
% |
Percentage NEK6 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase NEK7 |
Activity |
= |
105.0 |
% |
Percentage NEK7 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase p38 alpha |
Activity |
= |
95.0 |
% |
Percentage p38alpha activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Homeodomain-interacting protein kinase 2 |
Activity |
= |
99.0 |
% |
Percentage HIPK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Homeodomain-interacting protein kinase 3 |
Activity |
= |
101.0 |
% |
Percentage HIPK3 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Inhibitor of nuclear factor kappa B kinase beta subunit |
Activity |
= |
89.0 |
% |
Percentage IKK-beta activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| c-Jun N-terminal kinase 1 |
Activity |
= |
100.0 |
% |
Percentage JNK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase p38 beta |
Activity |
= |
90.0 |
% |
Percentage p38beta activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| c-Jun N-terminal kinase 2 |
Activity |
= |
96.0 |
% |
Percentage JNK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| c-Jun N-terminal kinase 3 |
Activity |
= |
100.0 |
% |
Percentage JNK3 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Tyrosine-protein kinase LCK |
Activity |
= |
74.0 |
% |
Percentage Lck activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase-activated protein kinase 2 |
Activity |
= |
106.0 |
% |
Percentage MAPKAPK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase-activated protein kinase 3 |
Activity |
= |
88.0 |
% |
Percentage MAPKAPK3 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase c-TAK1 |
Activity |
= |
89.0 |
% |
Percentage MARK3 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Maternal embryonic leucine zipper kinase |
Activity |
= |
72.0 |
% |
Percentage MELK activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Dual specificity mitogen-activated protein kinase kinase 1 |
Activity |
= |
104.0 |
% |
Percentage MKK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase-interacting serine/threonine-protein kinase MNK1 |
Activity |
= |
92.0 |
% |
Percentage MNK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase signal-integrating kinase 2 |
Activity |
= |
98.0 |
% |
Percentage MNK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Ribosomal protein S6 kinase alpha 5 |
Activity |
= |
89.0 |
% |
Percentage MSK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase MST2 |
Activity |
= |
60.0 |
% |
Percentage MST2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PLK1 |
Activity |
= |
81.0 |
% |
Percentage PLK1 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| MAP kinase-activated protein kinase 5 |
Activity |
= |
91.0 |
% |
Percentage PRAK activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Protein kinase N2 |
Activity |
= |
81.0 |
% |
Percentage PRK2 activity remaining in the presence of 0.1uM inhibitor |
CHEMBL1150976 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
70.0 |
nM |
Inhibition of CDK2 |
CHEMBL1156260 |
| Tyrosine-protein kinase SRC |
IC50 |
= |
240.0 |
nM |
Inhibition of SRC |
CHEMBL1156260 |
| Plasmodium falciparum |
IC50 |
= |
3000.0 |
nM |
Antimicrobial activity against Plasmodium falciparum |
CHEMBL1212812 |
| K562 |
Inhibition |
= |
75.1 |
% |
Cytotoxicity against human K562 cells assessed as inhibition of cell viability at 10 uM by MTT assay |
CHEMBL1240529 |
| NCI-H460 |
Inhibition |
= |
3.98 |
% |
Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability at 10 uM by MTT assay |
CHEMBL1240529 |
| ADMET |
Inhibition |
= |
88.6 |
% |
Cytotoxicity against human HDF cells assessed as inhibition of cell viability at 100 uM by MTT assay |
CHEMBL1240529 |
| HT-29 |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HT-29 cells by MTT assay |
CHEMBL1240529 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay |
CHEMBL1255231 |
| Menin/Histone-lysine N-methyltransferase MLL |
Potency |
= |
35481.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Endoplasmic reticulum-associated amyloid beta-peptide-binding protein |
Potency |
= |
31622.8 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Lysine-specific demethylase 4D-like |
Potency |
= |
31622.8 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) |
CHEMBL1201862 |
| Signal transducer and activator of transcription 6 |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: Parental Cell Counter Screen for Stat Signaling Pathway Assay. (Class of assay: confirmatory) [Related pubchem assays: 446 ] |
CHEMBL1201862 |
| Thyroid stimulating hormone receptor |
Potency |
= |
12.6 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Microtubule-associated protein tau |
Potency |
= |
4466.8 |
nM |
PUBCHEM_BIOASSAY: Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. This assay monitors tau fibrillation by fluorescence polarization (FP) of Alexa 594-labeled K18 P301L, which does not fibrillize readily but incorporates into growing filaments of unlabeled tau. (Class of assay: confirmatory) [Related pubchem assays: 596 ] |
CHEMBL1201862 |
| Cruzipain |
Potency |
= |
25118.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] |
CHEMBL1201862 |
| Cytochrome P450 2C19 |
Potency |
= |
31622.8 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19. (Class of assay: confirmatory) [Related pubchem assays: 410 ] |
CHEMBL1201862 |
| Microtubule-associated protein tau |
Potency |
= |
14125.4 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] |
CHEMBL1201862 |
| Aldehyde dehydrogenase 1A1 |
Potency |
= |
35481.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] |
CHEMBL1201862 |
| Hypoxia-inducible factor 1 alpha |
Potency |
= |
10000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 915 ] |
CHEMBL1201862 |
| Microtubule-associated protein tau |
Potency |
= |
11220.2 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. (Class of assay: confirmatory) [Related pubchem assays: 596 ] |
CHEMBL1201862 |
| Hypoxia-inducible factor 1 alpha |
Potency |
= |
10000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 914 ] |
CHEMBL1201862 |
| MAP kinase ERK2 |
Potency |
= |
31622.8 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Menin/Histone-lysine N-methyltransferase MLL |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Anthrax lethal factor |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Anthrax Lethal Toxin Internalization. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Signal transducer and activator of transcription 6 |
Potency |
= |
5011.9 |
nM |
PUBCHEM_BIOASSAY: Confirmation Concentration-Response Assay for Identification of Small Molecule Antagonists of Stat Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 446 ] |
CHEMBL1201862 |
| Nuclear receptor ROR-gamma |
Potency |
= |
14125.4 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cellular tumor antigen p53 |
Potency |
= |
10000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature. (Class of assay: confirmatory) [Related pubchem assays: 902 ] |
CHEMBL1201862 |
| Signal transducer and activator of transcription 6 |
Potency |
= |
5011.9 |
nM |
PUBCHEM_BIOASSAY: Confirmation Concentration-Response Assay for Identification of Small Molecule Agonists of Stat Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 446 ] |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Activators of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] |
CHEMBL1201862 |
| Cytochrome P450 2D6 |
Potency |
= |
39810.7 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6. (Class of assay: confirmatory) [Related pubchem assays: 410 ] |
CHEMBL1201862 |
| Cytochrome P450 2C9 |
Potency |
= |
7943.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ] |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] |
CHEMBL1201862 |
| Cytochrome P450 2C9 |
Potency |
= |
39810.7 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ] |
CHEMBL1201862 |
| Unchecked |
Potency |
= |
1258.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Lipid Storage Modulators. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Beta-glucocerebrosidase |
Potency |
|
19952.6 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1473, AID2293, AID2577, AID2578, AID2587, AID2588, AID2589, AID2590, AID2592, AID2593, AID2595, AID2596, AID2597, AID2613, AID2671, AID488845] |
CHEMBL1201862 |
| Arachidonate 15-lipoxygenase, type II |
Potency |
|
1995.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2312, AID2537, AID2702] |
CHEMBL1201862 |
| Cytochrome P450 2C9 |
AC50 |
= |
39810.72 |
nM |
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2C19 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
AC50 |
= |
12589.25 |
nM |
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 1A2 |
AC50 |
= |
316.23 |
nM |
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Cytochrome P450 2D6 |
AC50 |
|
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active |
CHEMBL1201862 |
| Ubiquitin carboxyl-terminal hydrolase 1 |
Potency |
|
50118.7 |
nM |
PUBCHEM_BIOASSAY: Inhibitors of USP1/UAF1: Pilot qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504878] |
CHEMBL1201862 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
|
|
|
Inhibition of CDK2/cyclin A using 5-FAM-GGGPATPKKAKKL-COOH as substrate after 1 hr by IMAP assay |
CHEMBL2010797 |
| Cyclin-dependent kinase 2/cyclin A |
Inhibition |
= |
94.0 |
% |
Inhibition of CDK2/cyclin A using 5-FAM-GGGPATPKKAKKL-COOH as substrate at 10 uM after 1 hr by IMAP assay |
CHEMBL2010797 |
| Serine/threonine-protein kinase MARK1 |
Residual Activity |
= |
78.0 |
% |
Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase SRPK3 |
Residual Activity |
= |
73.0 |
% |
Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase NEK6 |
Residual Activity |
= |
122.0 |
% |
Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase NEK7 |
Residual Activity |
= |
102.0 |
% |
Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase ABL2 |
Residual Activity |
= |
22.0 |
% |
Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase ABL2 |
Residual Activity |
= |
1.0 |
% |
Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 2/cyclin A |
Residual Activity |
= |
0.0 |
% |
Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase I isoform gamma-3 |
Residual Activity |
= |
13.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CaM kinase I delta |
Residual Activity |
= |
73.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| Death-associated protein kinase 1 |
Residual Activity |
= |
87.0 |
% |
Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-A receptor 4 |
Residual Activity |
= |
47.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Fibroblast growth factor receptor 3 |
Residual Activity |
= |
56.0 |
% |
Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase FYN |
Residual Activity |
= |
4.0 |
% |
Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 |
CHEMBL2218924 |
| Tyrosine-protein kinase FYN |
Residual Activity |
= |
-1.0 |
% |
Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 |
CHEMBL2218924 |
| Tyrosine-protein kinase HCK |
Residual Activity |
= |
30.0 |
% |
Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase HCK |
Residual Activity |
= |
4.0 |
% |
Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Inhibitor of nuclear factor kappa B kinase alpha subunit |
Residual Activity |
= |
114.0 |
% |
Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Inhibitor of nuclear factor kappa B kinase alpha subunit |
Residual Activity |
= |
126.0 |
% |
Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| c-Jun N-terminal kinase 3 |
Residual Activity |
= |
102.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| c-Jun N-terminal kinase 3 |
Residual Activity |
= |
108.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Serine/threonine-protein kinase MARK1 |
Residual Activity |
= |
46.0 |
% |
Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Dual specificity mitogen-activated protein kinase kinase 1 |
Residual Activity |
= |
111.0 |
% |
Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35 |
CHEMBL2218924 |
| Serine/threonine-protein kinase SRPK3 |
Residual Activity |
= |
17.0 |
% |
Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase MST1 |
Residual Activity |
= |
63.0 |
% |
Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase NEK7 |
Residual Activity |
= |
94.0 |
% |
Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Aurora-A |
Residual Activity |
= |
111.0 |
% |
Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase Aurora-A |
Residual Activity |
= |
72.0 |
% |
Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 |
CHEMBL2218924 |
| Cyclin-dependent kinase 2/cyclin E |
Residual Activity |
= |
2.0 |
% |
Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 2/cyclin E |
Residual Activity |
= |
-1.0 |
% |
Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase I delta |
Residual Activity |
= |
74.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase I delta |
Residual Activity |
= |
23.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Death-associated protein kinase 1 |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-A receptor 5 |
Residual Activity |
= |
83.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 |
CHEMBL2218924 |
| Ephrin type-A receptor 5 |
Residual Activity |
= |
14.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 |
CHEMBL2218924 |
| Fibroblast growth factor receptor 4 |
Residual Activity |
= |
118.0 |
% |
Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Fibroblast growth factor receptor 4 |
Residual Activity |
= |
116.0 |
% |
Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Mitogen-activated protein kinase kinase kinase kinase 2 |
Residual Activity |
= |
75.0 |
% |
Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA |
CHEMBL2218924 |
| Insulin-like growth factor I receptor |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Inhibitor of nuclear factor kappa B kinase beta subunit |
Residual Activity |
= |
116.0 |
% |
Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Vascular endothelial growth factor receptor 2 |
Residual Activity |
= |
105.0 |
% |
Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Dual specificity mitogen-activated protein kinase kinase 1 |
Residual Activity |
= |
104.0 |
% |
Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35 |
CHEMBL2218924 |
| Serine/threonine-protein kinase MST1 |
Residual Activity |
= |
30.0 |
% |
Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine protein kinase NLK |
Residual Activity |
= |
100.0 |
% |
Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine protein kinase NLK |
Residual Activity |
= |
81.0 |
% |
Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Aurora-B |
Residual Activity |
= |
72.0 |
% |
Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 |
CHEMBL2218924 |
| CDK3/cyclin E |
Residual Activity |
= |
14.0 |
% |
Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase II |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 |
CHEMBL2218924 |
| Death-associated protein kinase 2 |
Residual Activity |
= |
104.0 |
% |
Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Death-associated protein kinase 2 |
Residual Activity |
= |
103.0 |
% |
Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-A receptor 7 |
Residual Activity |
= |
76.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase FER |
Residual Activity |
= |
90.0 |
% |
Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 |
CHEMBL2218924 |
| Mitogen-activated protein kinase kinase kinase kinase 2 |
Residual Activity |
= |
23.0 |
% |
Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA |
CHEMBL2218924 |
| G protein-coupled receptor kinase 5 |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Insulin-like growth factor I receptor |
Residual Activity |
= |
136.0 |
% |
Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Inhibitor of nuclear factor kappa B kinase beta subunit |
Residual Activity |
= |
101.0 |
% |
Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Insulin receptor |
Residual Activity |
= |
81.0 |
% |
Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Vascular endothelial growth factor receptor 2 |
Residual Activity |
= |
58.0 |
% |
Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| LIM domain kinase 1 |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Maternal embryonic leucine zipper kinase |
Residual Activity |
= |
66.0 |
% |
Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Maternal embryonic leucine zipper kinase |
Residual Activity |
= |
18.0 |
% |
Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase MST2 |
Residual Activity |
= |
104.0 |
% |
Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase MST2 |
Residual Activity |
= |
35.0 |
% |
Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK 2 |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Aurora-B |
Residual Activity |
= |
17.0 |
% |
Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase Aurora-C |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 |
CHEMBL2218924 |
| CDK3/cyclin E |
Residual Activity |
= |
3.0 |
% |
Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
Residual Activity |
= |
0.0 |
% |
Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase II |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 |
CHEMBL2218924 |
| Casein kinase II alpha (prime) |
Residual Activity |
= |
110.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase DCLK2 |
Residual Activity |
= |
128.0 |
% |
Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-A receptor 7 |
Residual Activity |
= |
28.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-A receptor 8 |
Residual Activity |
= |
85.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| G protein-coupled receptor kinase 5 |
Residual Activity |
= |
82.0 |
% |
Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Insulin receptor |
Residual Activity |
= |
33.0 |
% |
Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| LIM domain kinase 1 |
Residual Activity |
= |
90.0 |
% |
Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Misshapen-like kinase 1 |
Residual Activity |
= |
103.0 |
% |
Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase 24 |
Residual Activity |
= |
58.0 |
% |
Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK 2 |
Residual Activity |
= |
79.0 |
% |
Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK 3 |
Residual Activity |
= |
100.0 |
% |
Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Aurora-C |
Residual Activity |
= |
78.0 |
% |
Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100 |
CHEMBL2218924 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
Residual Activity |
= |
0.0 |
% |
Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase II alpha (prime) |
Residual Activity |
= |
112.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase DCLK2 |
Residual Activity |
= |
139.0 |
% |
Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Discoidin domain-containing receptor 2 |
Residual Activity |
= |
91.0 |
% |
Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Ephrin type-A receptor 8 |
Residual Activity |
= |
46.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| G protein-coupled receptor kinase 6 |
Residual Activity |
= |
103.0 |
% |
Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| G protein-coupled receptor kinase 6 |
Residual Activity |
= |
82.0 |
% |
Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Insulin receptor |
Residual Activity |
= |
34.0 |
% |
Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate |
CHEMBL2218924 |
| Insulin receptor |
Residual Activity |
= |
4.0 |
% |
Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate |
CHEMBL2218924 |
| Serine/threonine-protein kinase 11 |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase 11 |
Residual Activity |
= |
86.0 |
% |
Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100 |
CHEMBL2218924 |
| Misshapen-like kinase 1 |
Residual Activity |
= |
80.0 |
% |
Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Dual specificity mitogen-activated protein kinase kinase 6 |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA |
CHEMBL2218924 |
| Serine/threonine-protein kinase 24 |
Residual Activity |
= |
20.0 |
% |
Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Proto-oncogene tyrosine-protein kinase MER |
Residual Activity |
= |
26.0 |
% |
Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl |
CHEMBL2218924 |
| Tyrosine kinase non-receptor protein 2 |
Residual Activity |
= |
45.0 |
% |
Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase receptor UFO |
Residual Activity |
= |
90.0 |
% |
Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase receptor UFO |
Residual Activity |
= |
31.0 |
% |
Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
Residual Activity |
= |
1.0 |
% |
Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
Residual Activity |
= |
0.0 |
% |
Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Dual specificity protein kinase CLK2 |
Residual Activity |
= |
8.0 |
% |
Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Dual specificity protein kinase CLK2 |
Residual Activity |
= |
1.0 |
% |
Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Discoidin domain-containing receptor 2 |
Residual Activity |
= |
92.0 |
% |
Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Ephrin type-B receptor 1 |
Residual Activity |
= |
63.0 |
% |
Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-B receptor 1 |
Residual Activity |
= |
15.0 |
% |
Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| G protein-coupled receptor kinase 7 |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Interleukin-1 receptor-associated kinase 1 |
Residual Activity |
= |
81.0 |
% |
Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase 10 |
Residual Activity |
= |
91.0 |
% |
Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Dual specificity mitogen-activated protein kinase kinase 6 |
Residual Activity |
= |
64.0 |
% |
Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA |
CHEMBL2218924 |
| Proto-oncogene tyrosine-protein kinase MER |
Residual Activity |
= |
0.0 |
% |
Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl |
CHEMBL2218924 |
| Tyrosine kinase non-receptor protein 2 |
Residual Activity |
= |
14.0 |
% |
Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| ALK tyrosine kinase receptor |
Residual Activity |
= |
71.0 |
% |
Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase BRK |
Residual Activity |
= |
109.0 |
% |
Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 |
CHEMBL2218924 |
| CDK6/cyclin D3 |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Dual specificity protein kinase CLK3 |
Residual Activity |
= |
55.0 |
% |
Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Dual specificity protein kinase CLK3 |
Residual Activity |
= |
11.0 |
% |
Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Myotonin-protein kinase |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Myotonin-protein kinase |
Residual Activity |
= |
89.0 |
% |
Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-B receptor 2 |
Residual Activity |
= |
71.0 |
% |
Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| G protein-coupled receptor kinase 7 |
Residual Activity |
= |
44.0 |
% |
Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Glycogen synthase kinase-3 alpha |
Residual Activity |
= |
104.0 |
% |
Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Interleukin-1 receptor-associated kinase 1 |
Residual Activity |
= |
23.0 |
% |
Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Interleukin-1 receptor-associated kinase 4 |
Residual Activity |
= |
45.0 |
% |
Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase 10 |
Residual Activity |
= |
37.0 |
% |
Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase LCK |
Residual Activity |
= |
28.0 |
% |
Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 |
CHEMBL2218924 |
| Dual specificity mitogen-activated protein kinase kinase 7 |
Residual Activity |
= |
75.0 |
% |
Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4 |
CHEMBL2218924 |
| Dual specificity mitogen-activated protein kinase kinase 7 |
Residual Activity |
= |
108.0 |
% |
Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4 |
CHEMBL2218924 |
| Hepatocyte growth factor receptor |
Residual Activity |
= |
83.0 |
% |
Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Hepatocyte growth factor receptor |
Residual Activity |
= |
73.0 |
% |
Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| ALK tyrosine kinase receptor |
Residual Activity |
= |
26.0 |
% |
Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase BRK |
Residual Activity |
= |
92.0 |
% |
Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 |
CHEMBL2218924 |
| Tyrosine-protein kinase BTK |
Residual Activity |
= |
56.0 |
% |
Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CDK6/cyclin D3 |
Residual Activity |
= |
44.0 |
% |
Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 7/ cyclin H |
Residual Activity |
= |
17.0 |
% |
Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase CSK |
Residual Activity |
= |
107.0 |
% |
Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2 |
CHEMBL2218924 |
| Serine/threonine-protein kinase 17A |
Residual Activity |
= |
116.0 |
% |
Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-B receptor 2 |
Residual Activity |
= |
3.0 |
% |
Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Ephrin type-B receptor 3 |
Residual Activity |
= |
77.0 |
% |
Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Tyrosine-protein kinase FER |
Residual Activity |
= |
26.0 |
% |
Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 |
CHEMBL2218924 |
| Glycogen synthase kinase-3 alpha |
Residual Activity |
= |
62.0 |
% |
Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Interleukin-1 receptor-associated kinase 4 |
Residual Activity |
= |
9.0 |
% |
Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase LCK |
Residual Activity |
= |
14.0 |
% |
Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4 |
CHEMBL2218924 |
| Myosin light chain kinase, smooth muscle |
Residual Activity |
= |
106.0 |
% |
Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| MAP kinase signal-integrating kinase 2 |
Residual Activity |
= |
111.0 |
% |
Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Activin receptor type-1B |
Residual Activity |
= |
115.0 |
% |
Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Activin receptor type-1B |
Residual Activity |
= |
111.0 |
% |
Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase BTK |
Residual Activity |
= |
17.0 |
% |
Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 7/ cyclin H |
Residual Activity |
= |
1.0 |
% |
Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase CSK |
Residual Activity |
= |
65.0 |
% |
Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2 |
CHEMBL2218924 |
| CaM kinase I alpha |
Residual Activity |
= |
93.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| Serine/threonine-protein kinase 17A |
Residual Activity |
= |
92.0 |
% |
Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 2 |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-B receptor 3 |
Residual Activity |
= |
104.0 |
% |
Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Tyrosine-protein kinase FES |
Residual Activity |
= |
79.0 |
% |
Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase FES |
Residual Activity |
= |
19.0 |
% |
Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Glycogen synthase kinase-3 beta |
Residual Activity |
= |
134.0 |
% |
Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Glycogen synthase kinase-3 beta |
Residual Activity |
= |
57.0 |
% |
Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Insulin receptor-related protein |
Residual Activity |
= |
83.0 |
% |
Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Insulin receptor-related protein |
Residual Activity |
= |
3.0 |
% |
Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase LCK |
Residual Activity |
= |
52.0 |
% |
Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase LCK |
Residual Activity |
= |
8.0 |
% |
Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Myosin light chain kinase, smooth muscle |
Residual Activity |
= |
46.0 |
% |
Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| Mitogen-activated protein kinase kinase kinase 9 |
Residual Activity |
= |
10.0 |
% |
Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| MAP kinase signal-integrating kinase 2 |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Muscle, skeletal receptor tyrosine protein kinase |
Residual Activity |
= |
48.0 |
% |
Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 |
CHEMBL2218924 |
| AMP-activated protein kinase (AMPK) alpha-1/beta-1/gamma-1 |
Residual Activity |
= |
92.0 |
% |
Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP |
CHEMBL2218924 |
| Tyrosine-protein kinase BLK |
Residual Activity |
= |
38.0 |
% |
Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Tyrosine-protein kinase BLK |
Residual Activity |
= |
2.0 |
% |
Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| CDK9/cyclin T1 |
Residual Activity |
= |
23.0 |
% |
Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CDK9/cyclin T1 |
Residual Activity |
= |
5.0 |
% |
Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CaM kinase I alpha |
Residual Activity |
= |
78.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 2 |
Residual Activity |
= |
86.0 |
% |
Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-B receptor 4 |
Residual Activity |
= |
37.0 |
% |
Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Ephrin type-B receptor 4 |
Residual Activity |
= |
4.0 |
% |
Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Tyrosine-protein kinase FGR |
Residual Activity |
= |
23.0 |
% |
Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Homeodomain-interacting protein kinase 1 |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase ITK/TSK |
Residual Activity |
= |
68.0 |
% |
Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase Lyn |
Residual Activity |
= |
11.0 |
% |
Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Mitogen-activated protein kinase kinase kinase 9 |
Residual Activity |
= |
1.0 |
% |
Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Muscle, skeletal receptor tyrosine protein kinase |
Residual Activity |
= |
5.0 |
% |
Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2 |
CHEMBL2218924 |
| AMP-activated protein kinase (AMPK) alpha-1/beta-1/gamma-1 |
Residual Activity |
= |
42.0 |
% |
Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP |
CHEMBL2218924 |
| AMP-activated protein kinase, AMPK |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP |
CHEMBL2218924 |
| Tyrosine-protein kinase BMX |
Residual Activity |
= |
34.0 |
% |
Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Chk1 |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CaM kinase II beta |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| CaM kinase II beta |
Residual Activity |
= |
68.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| Epidermal growth factor receptor erbB1 |
Residual Activity |
= |
109.0 |
% |
Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Epidermal growth factor receptor erbB1 |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Receptor protein-tyrosine kinase erbB-4 |
Residual Activity |
= |
105.0 |
% |
Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 |
CHEMBL2218924 |
| Tyrosine-protein kinase FGR |
Residual Activity |
= |
0.0 |
% |
Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Vascular endothelial growth factor receptor 1 |
Residual Activity |
= |
88.0 |
% |
Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Homeodomain-interacting protein kinase 1 |
Residual Activity |
= |
49.0 |
% |
Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Homeodomain-interacting protein kinase 2 |
Residual Activity |
= |
88.0 |
% |
Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase ITK/TSK |
Residual Activity |
= |
11.0 |
% |
Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase JAK2 |
Residual Activity |
= |
106.0 |
% |
Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase Lyn |
Residual Activity |
= |
0.0 |
% |
Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| MAP kinase ERK1 |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase MRCK-A |
Residual Activity |
= |
112.0 |
% |
Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase MRCK-A |
Residual Activity |
= |
118.0 |
% |
Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Nek11 |
Residual Activity |
= |
59.0 |
% |
Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Nek11 |
Residual Activity |
= |
38.0 |
% |
Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| AMP-activated protein kinase, AMPK |
Residual Activity |
= |
48.0 |
% |
Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP |
CHEMBL2218924 |
| Tyrosine-protein kinase BMX |
Residual Activity |
= |
5.0 |
% |
Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| BR serine/threonine-protein kinase 1 |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Chk1 |
Residual Activity |
= |
86.0 |
% |
Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Chk2 |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CaM kinase II gamma |
Residual Activity |
= |
100.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| Ephrin type-A receptor 1 |
Residual Activity |
= |
69.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Receptor protein-tyrosine kinase erbB-4 |
Residual Activity |
= |
115.0 |
% |
Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 |
CHEMBL2218924 |
| Focal adhesion kinase 1 |
Residual Activity |
= |
65.0 |
% |
Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Vascular endothelial growth factor receptor 1 |
Residual Activity |
= |
43.0 |
% |
Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Homeodomain-interacting protein kinase 2 |
Residual Activity |
= |
36.0 |
% |
Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase JAK2 |
Residual Activity |
= |
73.0 |
% |
Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| MAP kinase ERK1 |
Residual Activity |
= |
40.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase MRCK beta |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase NEK2 |
Residual Activity |
= |
90.0 |
% |
Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| NUAK family SNF1-like kinase 1 |
Residual Activity |
= |
84.0 |
% |
Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| NUAK family SNF1-like kinase 1 |
Residual Activity |
= |
33.0 |
% |
Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| BR serine/threonine-protein kinase 1 |
Residual Activity |
= |
87.0 |
% |
Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Chk2 |
Residual Activity |
= |
38.0 |
% |
Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CaM kinase II gamma |
Residual Activity |
= |
42.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| CaM kinase II delta |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| Ephrin type-A receptor 1 |
Residual Activity |
= |
14.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-A receptor 2 |
Residual Activity |
= |
69.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Focal adhesion kinase 1 |
Residual Activity |
= |
13.0 |
% |
Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase receptor FLT3 |
Residual Activity |
= |
17.0 |
% |
Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase receptor FLT3 |
Residual Activity |
= |
2.0 |
% |
Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Homeodomain-interacting protein kinase 3 |
Residual Activity |
= |
101.0 |
% |
Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Homeodomain-interacting protein kinase 3 |
Residual Activity |
= |
77.0 |
% |
Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase JAK3 |
Residual Activity |
= |
114.0 |
% |
Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase JAK3 |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| MAP kinase ERK2 |
Residual Activity |
= |
102.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase MRCK beta |
Residual Activity |
= |
88.0 |
% |
Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 5 |
Residual Activity |
= |
111.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase NEK2 |
Residual Activity |
= |
53.0 |
% |
Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Nek3 |
Residual Activity |
= |
84.0 |
% |
Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Mitogen-activated protein kinase kinase kinase 5 |
Residual Activity |
= |
102.0 |
% |
Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| BR serine/threonine-protein kinase 2 |
Residual Activity |
= |
122.0 |
% |
Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| BR serine/threonine-protein kinase 2 |
Residual Activity |
= |
106.0 |
% |
Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase I gamma 1 |
Residual Activity |
= |
10.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase I gamma 1 |
Residual Activity |
= |
1.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CaM kinase II delta |
Residual Activity |
= |
46.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| Ephrin type-A receptor 2 |
Residual Activity |
= |
27.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Fibroblast growth factor receptor 1 |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Fibroblast growth factor receptor 1 |
Residual Activity |
= |
15.0 |
% |
Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Vascular endothelial growth factor receptor 3 |
Residual Activity |
= |
42.0 |
% |
Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase haspin |
Residual Activity |
= |
100.0 |
% |
Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| c-Jun N-terminal kinase 1 |
Residual Activity |
= |
103.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol |
CHEMBL2218924 |
| MAP kinase ERK2 |
Residual Activity |
= |
33.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| MAP kinase-activated protein kinase 2 |
Residual Activity |
= |
81.0 |
% |
Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 5 |
Residual Activity |
= |
104.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Nek3 |
Residual Activity |
= |
89.0 |
% |
Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Mitogen-activated protein kinase kinase kinase 5 |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase ABL |
Residual Activity |
= |
62.0 |
% |
Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 1/cyclin B1 |
Residual Activity |
= |
18.0 |
% |
Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase I gamma 2 |
Residual Activity |
= |
22.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CaM kinase IV |
Residual Activity |
= |
107.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin |
CHEMBL2218924 |
| CaM kinase IV |
Residual Activity |
= |
60.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin |
CHEMBL2218924 |
| Ephrin type-A receptor 3 |
Residual Activity |
= |
86.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Fibroblast growth factor receptor 2 |
Residual Activity |
= |
104.0 |
% |
Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 |
CHEMBL2218924 |
| Vascular endothelial growth factor receptor 3 |
Residual Activity |
= |
3.0 |
% |
Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Macrophage colony stimulating factor receptor |
Residual Activity |
= |
70.0 |
% |
Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase haspin |
Residual Activity |
= |
94.0 |
% |
Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase HCK |
Residual Activity |
= |
20.0 |
% |
Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Insulin-like growth factor I receptor |
Residual Activity |
= |
48.0 |
% |
Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate |
CHEMBL2218924 |
| c-Jun N-terminal kinase 1 |
Residual Activity |
= |
103.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol |
CHEMBL2218924 |
| c-Jun N-terminal kinase 2 |
Residual Activity |
= |
90.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| MAP kinase-activated protein kinase 2 |
Residual Activity |
= |
88.0 |
% |
Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 4 |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 4 |
Residual Activity |
= |
62.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase NEK6 |
Residual Activity |
= |
117.0 |
% |
Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase ABL |
Residual Activity |
= |
14.0 |
% |
Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 1/cyclin B1 |
Residual Activity |
= |
1.0 |
% |
Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Cyclin-dependent kinase 2/cyclin A |
Residual Activity |
= |
3.0 |
% |
Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase I gamma 2 |
Residual Activity |
= |
-13.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Casein kinase I isoform gamma-3 |
Residual Activity |
= |
72.0 |
% |
Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| CaM kinase I delta |
Residual Activity |
= |
121.0 |
% |
Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin |
CHEMBL2218924 |
| Ephrin type-A receptor 3 |
Residual Activity |
= |
31.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ephrin type-A receptor 4 |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Fibroblast growth factor receptor 2 |
Residual Activity |
= |
56.0 |
% |
Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2 |
CHEMBL2218924 |
| Fibroblast growth factor receptor 3 |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Macrophage colony stimulating factor receptor |
Residual Activity |
= |
34.0 |
% |
Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase HCK |
Residual Activity |
= |
4.0 |
% |
Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Insulin-like growth factor I receptor |
Residual Activity |
= |
12.0 |
% |
Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate |
CHEMBL2218924 |
| c-Jun N-terminal kinase 2 |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| MAP kinase-activated protein kinase 3 |
Residual Activity |
= |
124.0 |
% |
Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA |
CHEMBL2218924 |
| MAP kinase-activated protein kinase 3 |
Residual Activity |
= |
84.0 |
% |
Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA |
CHEMBL2218924 |
| 3-phosphoinositide dependent protein kinase-1 |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| cAMP-dependent protein kinase alpha-catalytic subunit |
Residual Activity |
= |
106.0 |
% |
Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C eta |
Residual Activity |
= |
90.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Serine/threonine-protein kinase PIM2 |
Residual Activity |
= |
122.0 |
% |
Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase receptor TYRO3 |
Residual Activity |
= |
85.0 |
% |
Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 |
CHEMBL2218924 |
| Tyrosine-protein kinase receptor TYRO3 |
Residual Activity |
= |
78.0 |
% |
Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 |
CHEMBL2218924 |
| Serine/threonine-protein kinase SIK1 |
Residual Activity |
= |
85.0 |
% |
Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase SIK1 |
Residual Activity |
= |
16.0 |
% |
Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase tousled-like 2 |
Residual Activity |
= |
100.0 |
% |
Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase WNK3 |
Residual Activity |
= |
82.0 |
% |
Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| cAMP-dependent protein kinase alpha-catalytic subunit |
Residual Activity |
= |
103.0 |
% |
Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C theta |
Residual Activity |
= |
70.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C theta |
Residual Activity |
= |
26.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PIM3 |
Residual Activity |
= |
87.0 |
% |
Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase PIM3 |
Residual Activity |
= |
89.0 |
% |
Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100 |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 1 |
Residual Activity |
= |
77.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase SRPK1 |
Residual Activity |
= |
52.0 |
% |
Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase tousled-like 2 |
Residual Activity |
= |
81.0 |
% |
Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Testis-specific serine/threonine-protein kinase 1 |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase WNK3 |
Residual Activity |
= |
51.0 |
% |
Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase YES |
Residual Activity |
= |
4.0 |
% |
Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase AKT |
Residual Activity |
= |
113.0 |
% |
Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase AKT |
Residual Activity |
= |
114.0 |
% |
Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C iota |
Residual Activity |
= |
115.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase PLK1 |
Residual Activity |
= |
75.0 |
% |
Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 1 |
Residual Activity |
= |
19.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 3 |
Residual Activity |
= |
62.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase SRPK1 |
Residual Activity |
= |
-1.0 |
% |
Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase SRPK2 |
Residual Activity |
= |
32.0 |
% |
Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Testis-specific serine/threonine-protein kinase 1 |
Residual Activity |
= |
72.0 |
% |
Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase YES |
Residual Activity |
= |
0.0 |
% |
Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase AKT2 |
Residual Activity |
= |
105.0 |
% |
Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C iota |
Residual Activity |
= |
103.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 |
CHEMBL2218924 |
| Protein kinase C mu |
Residual Activity |
= |
81.0 |
% |
Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase PLK1 |
Residual Activity |
= |
45.0 |
% |
Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT |
CHEMBL2218924 |
| Serine/threonine-protein kinase PLK3 |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 3 |
Residual Activity |
= |
15.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase SRPK2 |
Residual Activity |
= |
2.0 |
% |
Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Testis-specific serine/threonine-protein kinase 2 |
Residual Activity |
= |
94.0 |
% |
Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Testis-specific serine/threonine-protein kinase 2 |
Residual Activity |
= |
79.0 |
% |
Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase ZAP-70 |
Residual Activity |
= |
118.0 |
% |
Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Tyrosine-protein kinase ZAP-70 |
Residual Activity |
= |
114.0 |
% |
Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Serine/threonine-protein kinase AKT2 |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase AKT3 |
Residual Activity |
= |
106.0 |
% |
Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C mu |
Residual Activity |
= |
86.0 |
% |
Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase PLK3 |
Residual Activity |
= |
87.0 |
% |
Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 2 |
Residual Activity |
= |
75.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 2 |
Residual Activity |
= |
21.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase 33 |
Residual Activity |
= |
89.0 |
% |
Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase 33 |
Residual Activity |
= |
53.0 |
% |
Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase TEC |
Residual Activity |
= |
63.0 |
% |
Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate |
CHEMBL2218924 |
| Death-associated protein kinase 3 |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK 3 |
Residual Activity |
= |
111.0 |
% |
Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase AKT3 |
Residual Activity |
= |
84.0 |
% |
Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase D2 |
Residual Activity |
= |
105.0 |
% |
Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase D2 |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100 |
CHEMBL2218924 |
| Serine/threonine-protein kinase PRKX |
Residual Activity |
= |
81.0 |
% |
Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PRKX |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 6 |
Residual Activity |
= |
40.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl |
CHEMBL2218924 |
| Serine/threonine-protein kinase PLK2 |
Residual Activity |
= |
101.0 |
% |
Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase TEC |
Residual Activity |
= |
8.0 |
% |
Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate |
CHEMBL2218924 |
| Tyrosine-protein kinase TIE-2 |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2 |
CHEMBL2218924 |
| Death-associated protein kinase 3 |
Residual Activity |
= |
108.0 |
% |
Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase RAF |
Residual Activity |
= |
73.0 |
% |
Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK 4 |
Residual Activity |
= |
31.0 |
% |
Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK 4 |
Residual Activity |
= |
4.0 |
% |
Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C alpha |
Residual Activity |
= |
104.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Protein kinase C alpha |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| cGMP-dependent protein kinase 1 beta |
Residual Activity |
= |
107.0 |
% |
Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP |
CHEMBL2218924 |
| Protein tyrosine kinase 2 beta |
Residual Activity |
= |
35.0 |
% |
Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase alpha 6 |
Residual Activity |
= |
24.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl |
CHEMBL2218924 |
| MAP kinase p38 alpha |
Residual Activity |
= |
88.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PLK2 |
Residual Activity |
= |
86.0 |
% |
Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase SYK |
Residual Activity |
= |
102.0 |
% |
Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Tyrosine-protein kinase TIE-2 |
Residual Activity |
= |
59.0 |
% |
Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2 |
CHEMBL2218924 |
| Serine/threonine-protein kinase RAF |
Residual Activity |
= |
43.0 |
% |
Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK7 |
Residual Activity |
= |
50.0 |
% |
Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C beta |
Residual Activity |
= |
108.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| cGMP-dependent protein kinase 1 beta |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP |
CHEMBL2218924 |
| cGMP-dependent protein kinase 1 beta |
Residual Activity |
= |
103.0 |
% |
Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP |
CHEMBL2218924 |
| Protein tyrosine kinase 2 beta |
Residual Activity |
= |
4.0 |
% |
Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase RIPK2 |
Residual Activity |
= |
91.0 |
% |
Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| MAP kinase p38 alpha |
Residual Activity |
= |
80.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Tyrosine-protein kinase SYK |
Residual Activity |
= |
60.0 |
% |
Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Nerve growth factor receptor Trk-A |
Residual Activity |
= |
3.0 |
% |
Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Nerve growth factor receptor Trk-A |
Residual Activity |
= |
1.0 |
% |
Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Stem cell growth factor receptor |
Residual Activity |
= |
117.0 |
% |
Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Stem cell growth factor receptor |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK7 |
Residual Activity |
= |
11.0 |
% |
Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK6 |
Residual Activity |
= |
57.0 |
% |
Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C beta |
Residual Activity |
= |
108.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Protein kinase C beta |
Residual Activity |
= |
120.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| cGMP-dependent protein kinase 1 beta |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP |
CHEMBL2218924 |
| Serine/threonine-protein kinase RIPK2 |
Residual Activity |
= |
85.0 |
% |
Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| MAP kinase p38 beta |
Residual Activity |
= |
101.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| MAP kinase p38 beta |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Mitogen-activated protein kinase kinase kinase 7 |
Residual Activity |
= |
73.0 |
% |
Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Mitogen-activated protein kinase kinase kinase 7 |
Residual Activity |
= |
20.0 |
% |
Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Neurotrophic tyrosine kinase receptor type 2 |
Residual Activity |
= |
8.0 |
% |
Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase SRC |
Residual Activity |
= |
23.0 |
% |
Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PAK6 |
Residual Activity |
= |
13.0 |
% |
Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C beta |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| MAP kinase-activated protein kinase 5 |
Residual Activity |
= |
102.0 |
% |
Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA |
CHEMBL2218924 |
| MAP kinase-activated protein kinase 5 |
Residual Activity |
= |
59.0 |
% |
Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA |
CHEMBL2218924 |
| Rho-associated protein kinase 1 |
Residual Activity |
= |
115.0 |
% |
Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Rho-associated protein kinase 1 |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| MAP kinase p38 gamma |
Residual Activity |
= |
109.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase TAO1 |
Residual Activity |
= |
82.0 |
% |
Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl |
CHEMBL2218924 |
| Neurotrophic tyrosine kinase receptor type 2 |
Residual Activity |
= |
0.0 |
% |
Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase TXK |
Residual Activity |
= |
66.0 |
% |
Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase SRC |
Residual Activity |
= |
-2.0 |
% |
Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase EEF2K |
Residual Activity |
= |
109.0 |
% |
Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| MAP/microtubule affinity-regulating kinase 2 |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| MAP/microtubule affinity-regulating kinase 2 |
Residual Activity |
= |
52.0 |
% |
Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C gamma |
Residual Activity |
= |
102.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Protein kinase N2 |
Residual Activity |
= |
104.0 |
% |
Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Rho-associated protein kinase 2 |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA |
CHEMBL2218924 |
| MAP kinase p38 gamma |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| MAP kinase p38 delta |
Residual Activity |
= |
108.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase TAO1 |
Residual Activity |
= |
26.0 |
% |
Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl |
CHEMBL2218924 |
| Serine/threonine-protein kinase TAO2 |
Residual Activity |
= |
98.0 |
% |
Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase TXK |
Residual Activity |
= |
16.0 |
% |
Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase EEF2K |
Residual Activity |
= |
109.0 |
% |
Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| PAS domain-containing serine/threonine-protein kinase |
Residual Activity |
= |
135.0 |
% |
Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C gamma |
Residual Activity |
= |
101.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Protein kinase C delta |
Residual Activity |
= |
107.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Protein kinase N2 |
Residual Activity |
= |
83.0 |
% |
Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Tyrosine-protein kinase FRK |
Residual Activity |
= |
59.0 |
% |
Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Rho-associated protein kinase 2 |
Residual Activity |
= |
76.0 |
% |
Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA |
CHEMBL2218924 |
| MAP kinase p38 delta |
Residual Activity |
= |
107.0 |
% |
Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase TAO2 |
Residual Activity |
= |
49.0 |
% |
Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase ULK2 |
Residual Activity |
= |
83.0 |
% |
Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase ULK2 |
Residual Activity |
= |
39.0 |
% |
Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase mTOR |
Residual Activity |
= |
101.0 |
% |
Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20 |
CHEMBL2218924 |
| Serine/threonine-protein kinase mTOR |
Residual Activity |
= |
100.0 |
% |
Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20 |
CHEMBL2218924 |
| PAS domain-containing serine/threonine-protein kinase |
Residual Activity |
= |
116.0 |
% |
Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Platelet-derived growth factor receptor alpha |
Residual Activity |
= |
109.0 |
% |
Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C delta |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Tyrosine-protein kinase FRK |
Residual Activity |
= |
9.0 |
% |
Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase receptor RET |
Residual Activity |
= |
91.0 |
% |
Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Tyrosine-protein kinase receptor RET |
Residual Activity |
= |
27.0 |
% |
Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Sgk1 |
Residual Activity |
= |
112.0 |
% |
Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Sgk1 |
Residual Activity |
= |
117.0 |
% |
Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase TAO3 |
Residual Activity |
= |
82.0 |
% |
Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase TAO3 |
Residual Activity |
= |
32.0 |
% |
Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase ULK3 |
Residual Activity |
= |
39.0 |
% |
Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase mTOR |
Residual Activity |
= |
101.0 |
% |
Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12 |
CHEMBL2218924 |
| Platelet-derived growth factor receptor alpha |
Residual Activity |
= |
105.0 |
% |
Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C epsilon |
Residual Activity |
= |
112.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Protein kinase C epsilon |
Residual Activity |
= |
92.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Phosphorylase kinase gamma subunit 2 |
Residual Activity |
= |
122.0 |
% |
Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Phosphorylase kinase gamma subunit 2 |
Residual Activity |
= |
82.0 |
% |
Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Macrophage-stimulating protein receptor |
Residual Activity |
= |
92.0 |
% |
Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Sgk2 |
Residual Activity |
= |
99.0 |
% |
Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase TBK1 |
Residual Activity |
= |
90.0 |
% |
Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase ULK3 |
Residual Activity |
= |
7.0 |
% |
Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase VRK2 |
Residual Activity |
= |
85.0 |
% |
Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase mTOR |
Residual Activity |
= |
109.0 |
% |
Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12 |
CHEMBL2218924 |
| Ribosomal protein S6 kinase 1 |
Residual Activity |
= |
88.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Platelet-derived growth factor receptor beta |
Residual Activity |
= |
107.0 |
% |
Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Platelet-derived growth factor receptor beta |
Residual Activity |
= |
111.0 |
% |
Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C zeta |
Residual Activity |
= |
101.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PIM1 |
Residual Activity |
= |
100.0 |
% |
Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Macrophage-stimulating protein receptor |
Residual Activity |
= |
86.0 |
% |
Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Proto-oncogene tyrosine-protein kinase ROS |
Residual Activity |
= |
106.0 |
% |
Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Serine/threonine-protein kinase Sgk2 |
Residual Activity |
= |
107.0 |
% |
Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase Sgk3 |
Residual Activity |
= |
107.0 |
% |
Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase TBK1 |
Residual Activity |
= |
66.0 |
% |
Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| TGF-beta receptor type I |
Residual Activity |
= |
95.0 |
% |
Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 |
CHEMBL2218924 |
| Serine/threonine-protein kinase VRK2 |
Residual Activity |
= |
30.0 |
% |
Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Ribosomal protein S6 kinase 1 |
Residual Activity |
= |
64.0 |
% |
Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| 3-phosphoinositide dependent protein kinase-1 |
Residual Activity |
= |
111.0 |
% |
Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol |
CHEMBL2218924 |
| Protein kinase C zeta |
Residual Activity |
= |
117.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Protein kinase C eta |
Residual Activity |
= |
100.0 |
% |
Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol |
CHEMBL2218924 |
| Serine/threonine-protein kinase PIM1 |
Residual Activity |
= |
68.0 |
% |
Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase PIM2 |
Residual Activity |
= |
116.0 |
% |
Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Proto-oncogene tyrosine-protein kinase ROS |
Residual Activity |
= |
96.0 |
% |
Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2 |
CHEMBL2218924 |
| Serine/threonine-protein kinase Sgk3 |
Residual Activity |
= |
97.0 |
% |
Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| TGF-beta receptor type I |
Residual Activity |
= |
93.0 |
% |
Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2 |
CHEMBL2218924 |
| Serine/threonine-protein kinase WNK2 |
Residual Activity |
= |
91.0 |
% |
Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Serine/threonine-protein kinase WNK2 |
Residual Activity |
= |
46.0 |
% |
Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA |
CHEMBL2218924 |
| Unchecked |
Inhibition |
= |
100.0 |
% |
Inhibition of porcine brain CK1 delta/epsilon using RRKHAAIGpSAYSITA as substrate at 0.1 uM measured after 30 mins by scintillation counting |
CHEMBL2311464 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Activity |
= |
88.0 |
% |
Inhibition of recombinant GST-fused human DYRK1A expressed in Escherichia coli using KKISGRLSPIMTEQ as substrate assessed as remaining activity at 0.1 uM |
CHEMBL2311464 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Activity |
= |
87.0 |
% |
Inhibition of recombinant GST-fused human DYRK1A expressed in Escherichia coli using KKISGRLSPIMTEQ as substrate assessed as remaining activity at 1 uM |
CHEMBL2311464 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
9441.1 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
9441.1 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
28183.8 |
nM |
PubChem BioAssay. qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) |
CHEMBL1201862 |
| DNA-(apurinic or apyrimidinic site) lyase |
Potency |
|
39810.7 |
nM |
PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
610.0 |
nM |
Inhibition of recombinant human full length His-tagged CDK1/Cyclin B expressed in baculovirus expression system using peptide substrate after 30 mins by fluorimetric assay |
CHEMBL3875171 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
IC50 |
= |
300.0 |
nM |
Inhibition of DYRK1A (unknown origin) by cell-based assay |
CHEMBL4265878 |
| SARS-CoV-2 |
Inhibition |
= |
-8.31 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging |
CHEMBL4303101 |
| Replicase polyprotein 1ab |
Inhibition |
= |
20.08 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| Replicase polyprotein 1ab |
Inhibition |
= |
11.18 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| SARS-CoV-2 |
Inhibition |
= |
0.74 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
5.6 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
0.74 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
5.6 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| HEK-293T |
Cell Viability |
= |
22.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
2.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
14.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
6.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
10.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
241.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
22.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
36.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
17.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
82.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
65.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
39.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
35.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
48.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
107.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
63.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
44.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
201.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
48.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
88.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
96.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
19.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
43.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
50.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
80.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
32.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
33.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
256.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
11.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
45.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
347.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
19.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
37.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
60.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
26.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
27.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
86.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
49.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
42.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
40.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
38.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
46.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
351.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
39.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
42.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
211.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
32.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
36.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
23.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
14.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
85.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
63.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
40.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
25.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
36.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
16.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
26.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
125.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
66.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
126.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
32.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
36.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
23.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
18.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
81.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
68.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
26.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
28.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
45.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
14.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
125.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
66.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
189.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
67.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
90.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
17.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
93.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
23.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
67.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
91.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
21.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
233.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
24.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
198.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
67.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
90.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
17.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
93.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
27.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
67.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
91.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
19.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
233.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
24.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
275.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
69.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
66.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
77.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
92.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
28.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
22.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
68.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
71.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
87.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
256.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
33.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
21.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
346.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
69.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
66.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
77.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
92.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
25.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
29.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
63.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
74.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
79.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
256.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
33.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
21.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
248.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
21.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
29.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
18.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
81.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
48.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
49.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
32.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
18.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
51.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
60.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
24.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
106.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
49.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
51.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
145.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
21.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
29.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
79.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
72.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
47.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
26.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
25.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
94.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
63.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
16.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
106.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
49.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
51.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
131.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
46.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
29.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
5.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
17.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
82.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
85.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
49.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
32.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
18.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
92.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
79.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
110.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
53.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
51.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
143.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
22.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
36.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
17.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
82.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
65.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
38.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
24.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
36.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
34.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
95.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
54.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
107.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
63.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
44.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
256.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
49.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
57.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
32.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
68.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
86.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
48.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
37.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
54.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
51.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
53.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
85.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
274.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
42.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
37.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
198.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
48.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
88.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
92.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
53.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
75.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
46.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
97.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
82.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
256.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
11.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
45.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
200.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
29.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
87.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
27.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
11.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
90.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
69.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
19.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
75.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
30.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
97.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
94.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
322.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
65.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
295.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
45.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
57.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
31.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
51.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
11.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
88.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
42.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
36.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
49.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
57.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
53.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
75.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
293.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
42.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
39.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
190.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
90.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
23.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
94.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
89.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
38.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
55.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
10.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
94.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
94.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
594.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
82.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
375.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
45.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
57.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
31.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
51.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
87.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
75.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
31.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
61.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
24.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
96.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
98.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
293.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
42.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
39.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
324.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
49.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
57.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
32.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
68.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
87.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
73.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
27.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
64.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
26.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
98.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
97.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
274.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
42.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
37.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
189.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
64.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
23.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
76.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
77.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
33.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
49.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
22.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
94.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
64.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
330.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
35.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
133.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
68.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
83.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
67.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
48.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
27.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
24.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
32.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
55.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
212.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
31.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
82.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
66.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
47.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
91.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
80.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
65.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
20.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
50.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
102.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
52.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
66.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
47.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
16.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
91.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
80.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
65.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
100.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
100.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
108.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
52.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
129.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
62.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
13.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
86.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
68.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
55.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
23.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
21.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
32.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
96.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
39.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
165.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
37.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
78.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
66.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
49.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
92.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
83.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
79.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
13.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
98.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
95.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
23.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
78.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
66.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
49.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
92.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
83.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
79.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
13.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
16.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
98.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
95.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
23.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
106.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
117.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
21.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
18.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
81.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
60.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
37.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
96.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
59.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
108.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
49.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
75.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
366.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
19.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
37.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
60.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
26.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
27.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
87.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
85.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
50.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
41.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
99.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
99.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
351.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
39.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
42.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
94.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
56.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
19.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
18.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
81.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
62.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
20.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
93.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
87.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
58.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
153.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
43.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
86.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
203.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
46.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
29.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
5.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
19.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
80.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
60.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
51.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
39.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
40.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
49.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
23.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
110.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
53.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
51.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
74.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
21.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
91.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
73.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
23.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
34.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
16.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
108.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
49.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
75.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
73.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
24.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
24.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
5.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
13.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
86.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
70.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
57.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
26.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
16.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
101.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
68.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
64.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
111.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
49.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
89.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
50.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
21.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
78.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
111.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
49.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
89.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
21.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
106.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
131.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
13.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
68.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
26.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
89.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
30.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
67.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
70.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
19.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
152.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
31.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
70.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
168.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
56.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
19.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
94.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
60.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
84.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
40.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
25.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
153.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
43.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
86.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
157.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
47.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
93.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
60.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
40.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
23.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
102.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
52.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
157.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
47.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
16.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
6.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
93.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
60.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
40.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
23.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
5.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
108.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
52.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
83.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
219.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
64.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
95.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
60.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
82.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
12.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
40.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
14.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
330.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
35.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
414.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
6.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
90.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
23.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
95.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
77.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
15.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
86.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
26.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
594.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
82.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
221.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
68.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
94.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
36.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
80.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
63.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
212.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
31.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
82.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
190.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
13.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
68.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
26.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
12.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
87.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
38.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
76.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
61.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
29.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
152.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
31.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
70.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
105.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
24.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
24.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
5.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
91.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
87.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
61.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
12.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
101.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
68.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
64.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
244.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
29.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
87.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
27.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
11.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
96.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
63.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
31.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
85.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
36.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
26.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
322.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
65.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
59.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
73.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
91.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
85.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
83.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
70.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
26.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
81.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
102.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
73.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
89.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
75.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
25.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
14.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
70.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
26.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
81.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
212.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
62.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
12.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
87.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
58.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
76.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
13.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
41.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
12.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
165.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
37.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
78.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| Tyrosine-protein kinase ABL |
Delta TM |
= |
7.039 |
C |
Thermal Shift Assay. Domain: start/stop: S229-K512 |
CHEMBL4632348 |
| Serine/threonine-protein kinase Aurora-A |
Delta TM |
= |
0.4026 |
C |
Thermal Shift Assay. Domain: start/stop: E122-S403 |
CHEMBL4632348 |
| Bromodomain-containing protein 4 |
Delta TM |
= |
-0.2347 |
C |
Thermal Shift Assay. Domain: start/stop: N44-E168 |
CHEMBL4632348 |
| Peregrin |
Delta TM |
= |
-1.5319999999999998 |
C |
Thermal Shift Assay. Domain: start/stop: M626-G746 |
CHEMBL4632348 |
| Cyclin-dependent kinase 2 |
Delta TM |
= |
7.584 |
C |
Thermal Shift Assay. Domain: start/stop: M1-L298 |
CHEMBL4632348 |
| Casein kinase I delta |
Delta TM |
= |
3.504 |
C |
Thermal Shift Assay. Domain: start/stop: M1-K294 |
CHEMBL4632348 |
| Fibroblast growth factor receptor 3 |
Delta TM |
= |
4.042 |
C |
Thermal Shift Assay. Domain: start/stop: P449-E759 |
CHEMBL4632348 |
| Glycogen synthase kinase-3 beta |
Delta TM |
= |
3.825 |
C |
Thermal Shift Assay. Domain: start/stop: M26-R383 |
CHEMBL4632348 |
| MAP kinase ERK2 |
Delta TM |
= |
3.236 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S360 |
CHEMBL4632348 |
| Transcription intermediary factor 1-alpha |
Delta TM |
= |
-1.533 |
C |
Thermal Shift Assay. Domain: start/stop: G861-E979 |
CHEMBL4632348 |
| Unchecked |
IC50 |
= |
4.0 |
nM |
Inhibition of recombinant Cdc2/CycB (unknown origin) |
CHEMBL5107985 |
| Unchecked |
IC50 |
= |
35.0 |
nM |
Inhibition of recombinant CDK2/CycE (unknown origin) |
CHEMBL5107985 |
| CDK2/Cyclin A2 |
IC50 |
= |
70.0 |
nM |
Inhibition of recombinant CDK2/CycA (unknown origin) |
CHEMBL5107985 |
| Cyclin-dependent kinase 4/cyclin D1 |
IC50 |
= |
850.0 |
nM |
Inhibition of recombinant CDK4/CycD1 (unknown origin) |
CHEMBL5107985 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
75.0 |
nM |
Inhibition of recombinant CDK5/p35 (unknown origin) |
CHEMBL5107985 |
| Cyclin-dependent kinase 4 |
IC50 |
= |
4.0 |
nM |
Inhibition of CDK4 (unknown origin) |
CHEMBL5131375 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
4.0 |
nM |
Inhibition of CDK2 (unknown origin) |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
EC50 |
= |
2210.0 |
nM |
Antiviral activity against HIV-1 |
CHEMBL5131375 |
| Unchecked |
IC50 |
= |
4.0 |
nM |
Inhibition of CDK2/cyclin B (unknown origin) |
CHEMBL5131375 |
| CDK2/Cyclin A2 |
IC50 |
= |
70.0 |
nM |
Inhibition of CDK2/cyclin A (unknown origin) |
CHEMBL5131375 |
| Unchecked |
IC50 |
= |
35.0 |
nM |
Inhibition of CDK2/cyclin E (unknown origin) |
CHEMBL5131375 |
| Cyclin-dependent kinase 4/cyclin D1 |
IC50 |
= |
850.0 |
nM |
Inhibition of CDK4/cyclin D1 (unknown origin) |
CHEMBL5131375 |
| Unchecked |
CC50 |
= |
18700.0 |
nM |
Cytotoxicity against human MDM cells |
CHEMBL5131375 |
| Human herpesvirus 3 |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against VZV |
CHEMBL5131375 |
| Adhesion G-protein coupled receptor F1 |
%Max (Mean) |
= |
11.4 |
% |
GPCR beta-arrestin recruitment assay with target: ADGRF1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Adhesion G-protein coupled receptor F1 |
%Inhib (Mean) |
= |
43.07 |
% |
GPCR beta-arrestin recruitment assay with target: ADGRF1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| C-X3-C chemokine receptor 1 |
%Max (Mean) |
= |
-1.894 |
% |
GPCR beta-arrestin recruitment assay with target: CX3CR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| C-X3-C chemokine receptor 1 |
%Inhib (Mean) |
= |
30.86 |
% |
GPCR beta-arrestin recruitment assay with target: CX3CR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Apelin receptor |
%Max (Mean) |
= |
-0.34700000000000003 |
% |
GPCR beta-arrestin recruitment assay with target: APLNR Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Apelin receptor |
%Inhib (Mean) |
= |
-69.49 |
% |
GPCR beta-arrestin recruitment assay with target: APLNR Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Sphingosine 1-phosphate receptor Edg-1 |
%Inhib (Mean) |
= |
61.07 |
% |
GPCR beta-arrestin recruitment assay with target: S1PR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Sphingosine 1-phosphate receptor Edg-1 |
%Inhib (Mean) |
= |
-57.11 |
% |
GPCR beta-arrestin recruitment assay with target: S1PR1 Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| Sphingosine 1-phosphate receptor Edg-1 |
%Inhib (Mean) |
= |
-23.73 |
% |
GPCR beta-arrestin recruitment assay with target: S1PR1 Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| G-protein coupled receptor 120 |
%Max (Mean) |
= |
-1.8 |
% |
GPCR beta-arrestin recruitment assay with target: FFAR4 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| G-protein coupled receptor 120 |
%Inhib (Mean) |
= |
-64.9 |
% |
GPCR beta-arrestin recruitment assay with target: FFAR4 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Glucagon-like peptide 1 receptor |
%Inhib (Mean) |
= |
-50.55 |
% |
GPCR beta-arrestin recruitment assay with target: GLP1R Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Glucagon-like peptide 1 receptor |
%Inhib (Mean) |
= |
-106.18 |
% |
GPCR beta-arrestin recruitment assay with target: GLP1R Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| Glucagon-like peptide 1 receptor |
%Inhib (Mean) |
= |
-20.79 |
% |
GPCR beta-arrestin recruitment assay with target: GLP1R Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| Alpha-2a adrenergic receptor |
%Max (Mean) |
= |
2.8 |
% |
GPCR beta-arrestin recruitment assay with target: ADRA2A Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Alpha-2a adrenergic receptor |
%Inhib (Mean) |
= |
41.3 |
% |
GPCR beta-arrestin recruitment assay with target: ADRA2A Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Glucagon-like peptide 1 receptor |
%Max (Mean) |
= |
0.03 |
% |
GPCR beta-arrestin recruitment assay with target: GLP1R Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Glucagon-like peptide 1 receptor |
%Inhib (Mean) |
= |
59.16 |
% |
GPCR beta-arrestin recruitment assay with target: GLP1R Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Beta-2 adrenergic receptor |
%Inhib (Mean) |
= |
61.64 |
% |
GPCR beta-arrestin recruitment assay with target: ADRB2 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Beta-2 adrenergic receptor |
%Inhib (Mean) |
= |
-194.76 |
% |
GPCR beta-arrestin recruitment assay with target: ADRB2 Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| Beta-2 adrenergic receptor |
%Inhib (Mean) |
= |
-40.75 |
% |
GPCR beta-arrestin recruitment assay with target: ADRB2 Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| G-protein coupled receptor 35 |
%Max (Mean) |
= |
21.91 |
% |
GPCR beta-arrestin recruitment assay with target: GPR35 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| G-protein coupled receptor 35 |
%Inhib (Mean) |
= |
52.44 |
% |
GPCR beta-arrestin recruitment assay with target: GPR35 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Type-1 angiotensin II receptor |
%Max (Mean) |
= |
-2.019 |
% |
GPCR beta-arrestin recruitment assay with target: AGTR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Type-1 angiotensin II receptor |
%Inhib (Mean) |
= |
81.17 |
% |
GPCR beta-arrestin recruitment assay with target: AGTR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Apelin receptor |
%Inhib (Mean) |
= |
72.29 |
% |
GPCR beta-arrestin recruitment assay with target: APLNR Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Apelin receptor |
%Inhib (Mean) |
= |
-127.23 |
% |
GPCR beta-arrestin recruitment assay with target: APLNR Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| Apelin receptor |
%Inhib (Mean) |
= |
-17.54 |
% |
GPCR beta-arrestin recruitment assay with target: APLNR Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| Lipoxin A4 receptor |
%Inhib (Mean) |
= |
-36.61 |
% |
GPCR beta-arrestin recruitment assay with target: FPR2 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Lipoxin A4 receptor |
%Inhib (Mean) |
= |
-23.22 |
% |
GPCR beta-arrestin recruitment assay with target: FPR2 Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| Lipoxin A4 receptor |
%Inhib (Mean) |
= |
-19.3 |
% |
GPCR beta-arrestin recruitment assay with target: FPR2 Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| C-X3-C chemokine receptor 1 |
%Inhib (Mean) |
= |
-65.25 |
% |
GPCR beta-arrestin recruitment assay with target: CX3CR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| C-X3-C chemokine receptor 1 |
%Inhib (Mean) |
= |
-31.88 |
% |
GPCR beta-arrestin recruitment assay with target: CX3CR1 Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| C-X3-C chemokine receptor 1 |
%Inhib (Mean) |
= |
-44.22 |
% |
GPCR beta-arrestin recruitment assay with target: CX3CR1 Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| C5a anaphylatoxin chemotactic receptor |
%Max (Mean) |
= |
5.688 |
% |
GPCR beta-arrestin recruitment assay with target: C5AR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| C5a anaphylatoxin chemotactic receptor |
%Inhib (Mean) |
= |
-51.2 |
% |
GPCR beta-arrestin recruitment assay with target: C5AR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| G-protein coupled receptor 120 |
%Inhib (Mean) |
= |
-26.47 |
% |
GPCR beta-arrestin recruitment assay with target: FFAR4 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| G-protein coupled receptor 120 |
%Inhib (Mean) |
= |
-226.32 |
% |
GPCR beta-arrestin recruitment assay with target: FFAR4 Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| G-protein coupled receptor 120 |
%Inhib (Mean) |
= |
-55.84 |
% |
GPCR beta-arrestin recruitment assay with target: FFAR4 Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| Lipoxin A4 receptor |
%Max (Mean) |
= |
-3.64 |
% |
GPCR beta-arrestin recruitment assay with target: FPR2 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Lipoxin A4 receptor |
%Inhib (Mean) |
= |
26.66 |
% |
GPCR beta-arrestin recruitment assay with target: FPR2 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Type-1 angiotensin II receptor |
%Inhib (Mean) |
= |
30.47 |
% |
GPCR beta-arrestin recruitment assay with target: AGTR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Type-1 angiotensin II receptor |
%Inhib (Mean) |
= |
-10.35 |
% |
GPCR beta-arrestin recruitment assay with target: AGTR1 Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| Type-1 angiotensin II receptor |
%Inhib (Mean) |
= |
13.8 |
% |
GPCR beta-arrestin recruitment assay with target: AGTR1 Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| Sphingosine 1-phosphate receptor Edg-1 |
%Max (Mean) |
= |
17.87 |
% |
GPCR beta-arrestin recruitment assay with target: S1PR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Sphingosine 1-phosphate receptor Edg-1 |
%Inhib (Mean) |
= |
-25.1 |
% |
GPCR beta-arrestin recruitment assay with target: S1PR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Adhesion G-protein coupled receptor F1 |
%Inhib (Mean) |
= |
-81.92 |
% |
GPCR beta-arrestin recruitment assay with target: ADGRF1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Adhesion G-protein coupled receptor F1 |
%Inhib (Mean) |
= |
-34.93 |
% |
GPCR beta-arrestin recruitment assay with target: ADGRF1 Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| Adhesion G-protein coupled receptor F1 |
%Inhib (Mean) |
= |
-27.35 |
% |
GPCR beta-arrestin recruitment assay with target: ADGRF1 Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| C5a anaphylatoxin chemotactic receptor |
%Inhib (Mean) |
= |
-57.22 |
% |
GPCR beta-arrestin recruitment assay with target: C5AR1 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| C5a anaphylatoxin chemotactic receptor |
%Inhib (Mean) |
= |
-45.85 |
% |
GPCR beta-arrestin recruitment assay with target: C5AR1 Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| C5a anaphylatoxin chemotactic receptor |
%Inhib (Mean) |
= |
-26.04 |
% |
GPCR beta-arrestin recruitment assay with target: C5AR1 Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| Beta-2 adrenergic receptor |
%Max (Mean) |
= |
-1.94 |
% |
GPCR beta-arrestin recruitment assay with target: ADRB2 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Beta-2 adrenergic receptor |
%Inhib (Mean) |
= |
14.95 |
% |
GPCR beta-arrestin recruitment assay with target: ADRB2 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Glucose-dependent insulinotropic receptor |
%Max (Mean) |
= |
11.35 |
% |
GPCR beta-arrestin recruitment assay with target: GPR119 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Glucose-dependent insulinotropic receptor |
%Inhib (Mean) |
= |
36.46 |
% |
GPCR beta-arrestin recruitment assay with target: GPR119 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Glucose-dependent insulinotropic receptor |
%Inhib (Mean) |
= |
64.47 |
% |
GPCR beta-arrestin recruitment assay with target: GPR119 Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Glucose-dependent insulinotropic receptor |
%Inhib (Mean) |
= |
-121.34 |
% |
GPCR beta-arrestin recruitment assay with target: GPR119 Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| Glucose-dependent insulinotropic receptor |
%Inhib (Mean) |
= |
-58.81 |
% |
GPCR beta-arrestin recruitment assay with target: GPR119 Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
| Alpha-2a adrenergic receptor |
%Inhib (Mean) |
= |
-9.11 |
% |
GPCR beta-arrestin recruitment assay with target: ADRA2A Assay Type: PRESTO-Tango Concentration: 0.00001 |
CHEMBL5209801 |
| Alpha-2a adrenergic receptor |
%Inhib (Mean) |
= |
-44.05 |
% |
GPCR beta-arrestin recruitment assay with target: ADRA2A Assay Type: PRESTO-Tango Concentration: 0.000002 |
CHEMBL5209801 |
| Alpha-2a adrenergic receptor |
%Inhib (Mean) |
= |
-5.45 |
% |
GPCR beta-arrestin recruitment assay with target: ADRA2A Assay Type: PRESTO-Tango Concentration: 0.0000004 |
CHEMBL5209801 |
